


RECEIVED

SEP 0 2002
TECH CENTER 1600/2900



FORM PTO-1449
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
100103.403

APPLICATION NO.
10/090,458

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

APPLICANT
Hongyun Chen et al.

FILING DATE
March 1, 2002

GROUP ART UNIT
1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
				YES NO
AB	WO 98/48784	11/05/98	WIPO	

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	Allikmets et al., "Mutation of the Stargardt disease gene (<i>ABCR</i>) in age-related macular degeneration," <i>Science</i> 277(5333):1805-1807, September 19, 1997.
AD	Ambudkar et al., "Biochemical, cellular, and pharmacological aspects of the multidrug transporter," <i>Annu. Rev. Pharmacol. Toxicol.</i> 39:361-398, 1999.
AE	Bodzioch et al., "The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease," <i>Nature Genetics</i> 22:347-351, August 1999.
AF	Boer et al., "Modulation of P-glycoprotein mediated drug accumulation in multidrug resistant CCRF VCR-1000 cells by chemosensitisers," <i>European Journal of Cancer</i> 32A(5):857-861, May 1996.
AG	Borst, "Introduction: Multidrug resistant proteins," <i>Seminar in Cancer Biology</i> 8(3):131-134, June 1997.
AH	Brooks-Wilson et al., "Mutations in <i>ABCI</i> in Tangier disease and familial high-density lipoprotein deficiency," <i>Nature Genetics</i> 22(4):336-345, August 1999.
AI	Connop et al., "Novel Effects of FCCP [Carbonyl Cyanide <i>p</i> -(Trifluoromethoxy)phenylhydrazone] on Amyloid Precursor Protein Processing," <i>J. Neurochem.</i> 72(4):1457-1465, April 1999.
AJ	Games et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <i>Nature</i> 373(6514):523-527, February 9, 1995.
AK	Goate et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <i>Nature</i> 349(6311):704-706, February 21, 1991.
AL	Hamon et al., "Interleukin-1 β secretion is impaired by inhibitors of the Atp binding cassette transporter, ABC1," <i>Blood</i> 90(8):2911-2915, October 15, 1997.
AM	Hardy and Gwinn-Hardy, "Genetic classification of primary neurodegenerative disease," <i>Science</i> 282(5391):1075-1079, November 6, 1998.
AN	Higgins, "The ABC of Channel Regulation," <i>Cell</i> 82(5):693-696, September 8, 1995.
AO	Higgins, "Volume-activated chloride currents associated with the multidrug resistance P-glycoprotein," <i>J. Physiol.</i> 482:31S-36S, January 1995.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
100103.403APPLICATION NO.
10/090,468

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT

Hongyun Chen et al.

FILING DATE

March 1, 2002

GROUP ART UNIT

1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
				YES NO
BB				


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	Ling, "Multidrug resistance: molecular mechanisms and clinical relevance," <i>Cancer Chemother. Pharmacol.</i> 40(Suppl.):S3-S8, 1997.
BD	Mills et al., "Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway," <i>J. Neuroscience</i> 17(24):9415-9422, December 15, 1997.
BE	Mosser et al., "Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters," <i>Nature</i> 361(6414):726-730, February 25, 1993.
BF	Nakamura et al., "Polymorphisms of the human homologue of the <i>Drosophila</i> white gene are associated with mood and panic disorders," <i>Mol. Psychiatry</i> 4(2):155-162, March 1999.
BG	Patel and Latterich, "The AAA team: related ATPases with diverse functions," <i>Trends Cell Biol</i> 8(2):65-71, February 1998.
BH	Riordin et al., "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA," <i>Science</i> 245(4922):1066-1073, September 8, 1989.
BI	Rust et al., "Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1," <i>Nature Genetics</i> 22(4):352-355, August 1999.
BJ	Schinkel et al., "Disruption of the mouse <i>mdr1a</i> P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs," <i>Cell</i> 77(4):491-502, May 20, 1994.
BK	Suzuki et al., "An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (β APP ₇₁₇) mutants," <i>Science</i> 264(5163):1336-1340, May 27, 1994.
BL	Thomas et al., "Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy," <i>Science</i> 268(5209):426-429, April 21, 1995.
BM	Wolozin and Behl, "Mechanisms of Neurodegenerative Disorders: Part I: Protein Aggregates," <i>Arch. Neurol.</i> 57(6):793-796, June 2000.
BN	Zagotta and Siegelbaum, "Structure and function of cyclic nucleotide-gated channels," <i>Annual Rev. Neurosci.</i> 19:235-263, 1996.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Hongyun Chen et al.
Application No. : 10/090,458
Filed : March 1, 2002
For : NOVEL ABCA5 TRANSPORTER AND USES THEREOF

Art Unit : 1645
Docket No. : 100103.403
Date : September 6, 2002

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed).

As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Hongyun Chen et al.
Seed Intellectual Property Law Group PLLC



William T. Christiansen, Ph.D.
Registration No. 44,614


WTC:HPM:ljd

Enclosures:

Postcard
Form PTO/SB/21
Forms PTO-1449 (2 Sheets)
Cited References (26)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

D:\NrPortbl\iManage\PATTEMP\314966_1.DOC



Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence
after initial filing)



Application Number	10/090,458
Filing Date	March 1, 2002
First Named Inventor	Hongyun Chen
Group Art Unit	1645
Examiner Name	
Attorney Docket No.	100103.403

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Forms PTO-1449 (2 Sheets) <input checked="" type="checkbox"/> Cited References (26) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
--	---	--

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	William T. Christiansen, Ph.D. Reg. No. 44,614	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	September 6, 2002	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.		
Typed or printed name	Larry Dobson	
Signature		Date: September 6, 2002

6158645
9/10/02
RECEIVED
SEP 0 2002
FBI CENTER 160012900